N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide

• ChemBase编号: 589
• 分子式: C22H30N2O2S
• 平均质量: 386.5508
• 单一同位素质量: 386.20279921
• SMILES: s1c(CCN2CCC(N(c3ccccc3)C(=O)CC)(CC2)COC)ccc1
• Canonical SMILES: COCC1(CCN(CC1)CCc1cccs1)N(c1ccccc1)C(=O)CC
• InChI: InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
• InChIKey: GGCSSNBKKAUURC-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide
• IUPAC传统名: sufentanil
• 商标名: Chronogesic; Sufenta
• 别名: Sufentanil Citrate; Sufentanilum [INN-Latin]; Sufentanyl; Sulfentanil Citrate; sufentanil; Sufentanil

登记号

• CAS号: 56030-54-7
• PubChem SID: 46504737; 160964052
• PubChem CID: 41693
• CHEBI ID: 9316
• ATC码: N01AH03
• CHEMBL: 658
• Chemspider ID: 38043
• DrugBank ID: DB00708
• IUPHAR配体索引: 3534
• KEGG ID: D05938
• 美国药典/FDA物质标识码: AFE2YW0IIZ
• 维基百科标题: Sufentanil

理论计算性质

JChem

• 质子受体: 3
• 质子供体: 0
• LogD (pH = 5.5): 0.47834045
• LogD (pH = 7.4): 2.129825
• Log P: 3.605173
• 摩尔折射率: 111.4159 cm^3
• 极化性: 43.275696 Å^3
• 极化表面积: 32.78 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.4
• LOG S: -4.51
• 溶解度: 1.20e-02 g/l

分子性质

理化性质

• 溶解度: 76 mg/L
• 熔点: 97°C (206.6°F)
• 疏水性(logP): 2.8

药理学性质

• 给药途径: Injection
• 半衰期: 265 minutes
• 法定药品分级: Class A (UK); Schedule II (US)

详细说明

DrugBank - DB00708

• Drug Groups: approved; investigational
• Description: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]
• Indication: Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.
• Pharmacology: Sufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.
• Toxicity: LD₅₀: 18.7 mg/kg (IV in mice)
• Affected Organisms: Humans and other mammals
• Half Life: 265 minutes
• External Links: Wikipedia; Drugs.com